Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Abbott transfers joint diabetes collaboration rights to Karo Bio

Nov. 17, 2003

Aventis Pharma scientists design new glycogen phosphorylase inhibitors

Nov. 17, 2003

Novel estrogen receptor modulators prepared and tested by Wyeth researchers

Nov. 14, 2003

Pfizer presents two series of PPAR modulators with potential as antidiabetic agents

Nov. 14, 2003

Esteve scientists claim new NPY Y5 modulators for obesity and other uses

Nov. 14, 2003

Completion of first dose level in Oxycyte phase I study

Nov. 13, 2003

Exenatide meets glucose control endpoint in second of three pivotal trials

Nov. 13, 2003

Merck claims novel cannabinoid CB1 modulators with utility as antiobesity agents

Nov. 13, 2003

Novo Nordisk obtains license option for Islet Neogenesis Therapy

Nov. 12, 2003

Milestone reached in osteoporosis collaboration between Celltech and Amgen

Nov. 12, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...